Aptevo Therapeutics provides pipeline update via investor presentation

Aptevo Therapeutics Inc.

Presentation highlights clinical candidates mipletamig and ALG.APV-527.
Preclinical candidates APVO711, APVO603, APVO442 are also detailed.
No new clinical data, trial results, or financial guidance provided.
Presentation dated February 11, 2025, furnished under Regulation FD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.